Latest Market Access News

Nanoveu Limited reveals significant progress in its ECS-DoT system-on-chip technology, showcasing a 60% average increase in drone flight endurance and advancing production with TSMC’s 16nm process. The company’s latest investor webinar highlights its growing OEM partnerships and disruptive edge AI capabilities.

Sunrise Energy Metals Limited has had its trading suspension lifted following a fresh update to the Mineral Resource Estimate for its Syerston Scandium Project, signaling renewed market activity.

Artrya Limited has raised A$75 million through a two-tranche placement and launched a A$5 million share purchase plan to fast-track the U.S. commercialisation of its AI-powered Salix platform following FDA clearance.

Red Sky Energy has secured regulatory approval to build the KN2 well site at its Killanoola Oil Project, setting the stage for drilling a promising new target that could boost production and revenues.

Conico Limited has had its ASX trading suspension lifted immediately following an announcement detailing its capital raising and exploration plans, signaling renewed investor interest.

Austral Resources has finalized key agreements with Glencore, including tolling, loan, and offtake contracts, paving the way for its acquisition of the Rocklands copper project and expanding its footprint in Queensland.

Beetaloo Energy is gearing up for first gas production in 2026 from its Carpentaria Pilot Project, backed by a $65 million financing package and a binding 10-year gas sales agreement with the Northern Territory government.

Delorean Corporation reported a strategic shift in FY25, transitioning from third-party bioenergy construction to owning and operating renewable gas infrastructure, resulting in a $4.1 million loss but positioning the company for future multi-revenue growth.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.